A multidisciplinary project for personalized ovarian cancer therapy selection, termed 3D-SELECT, was granted EUR €3.47 million, of which total subsidy ~ €1.82 million, on June 25, 2019. The European consortium consist of six collaborating partners: VitroScan (lead), Anapath, FHNW, Uppsala University, Oncodia, and Robovision. The project combines expertise in 3D cell culturing, pathology, genomics, proteomics and AI to accelerate the development of the 3D SELECT platform to analyse drug response on small tumour biopsies from individual patients and identify the most efficacious treatment.
Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020.
